„Das Ziel ist: Weniger Nebenwirkungen, mehr Compliance“
Crossref DOI link: https://doi.org/10.1007/BF03363047
Published Online: 2016-06-28
Published Print: 2011-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
